Search clinical trials for: Rilotumumab

Total 17 results

Katy Peters
Amgen

Completed

AMG 102 and Avastin for Recurrent Malignant Glioma

Glioblastoma Multiforme | Gliosarcoma

United States
Amgen

Completed

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Part 1- Advanced Solid Tumors | Part 2- Advanced or Metastatic Gastric Cancer | Part 2- Advanced or Metastatic GEJ

Japan
Amgen

Completed

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal Cancer
National Cancer Institute (NCI)

Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
Ahmad Tarhini
Amgen

Completed

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Amgen

Terminated

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (RILOMET-2)

Gastric Cancer

Korea, Republic of, Japan
Amgen

Completed

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma
Amgen

Completed

A Phase II Study to Treat Advanced Malignant Glioma

Advanced Malignant Glioma
NantCell, Inc.

Completed

QUILT-2.013: A Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | Extensive-stage Small Cell Lung Cancer | Solid Tumors
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Amgen

Completed

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Gastric Cancer | Esophageal Cancer | Esophagogastric Junction Adenocarcinoma
Amgen

Terminated

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

Gastric Cancer

United States, Italy, Belgium, Hungary, Poland, Romania, Denmark, Switzerland, Canada, France, Germany, Russian Federation, Turkey, United Kingdom, Spain, Austria, Portugal, Australia, Greece, South Africa, Bulgaria, Ukraine, Brazil, ... and more
UNICANCER

Completed

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma (MEGA)

Malignant Neoplasm of Stomach | Malignant Neoplasm of Esophagus

France
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | MET Positive

United States
Amgen

Completed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Cancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
Lagos State University

Unknown

Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)

Other Sickle-cell Disorders With Crisis, Unspecified

Nigeria
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada

Search clinical trials for: Rilotumumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations